All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Mutation testing in AML:
What you need to know

with Charles Craddock, Ralph Hills, and Gail Roboz

Wednesday, April 23, 2025
17:30-18:30 BST

Register now

This independent educational activity is supported by Thermo Fisher Scientific. All content is developed independently by the faculty. The funder is allowed no influence on the content.

  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2018-06-07T20:49:56.000Z

ASCO 2018 | Venetoclax in combination with decitabine or azacitidine in elderly patients with AML induces durable response

Jun 7, 2018
Share:

Bookmark this article

In February 2018, the AGP reported data as of cut-off date of June 2016 from a dual-stage, non-randomized phase Ib study (NCT02203773), which is assessing the safety and efficacy of venetoclax (VEN), a BCL2 inhibitor, in combination with decitabine (DEC) or azacitidine (AZA) in previously untreated older acute myeloid leukemia (AML) patients who are ineligible for standard induction therapy. Preliminary findings of this study demonstrated that VEN plus AZA or DEC was “well tolerated” in newly diagnosed patients with AML who are unfit for standard chemotherapy with promising preliminary efficacy and low early mortality rate.1

The updated data from this phase Ib study was presented by Courtney DiNardo at the 2018 American Society of Oncology (ASCO) Annual Meeting. Overall, 145 patients (median age = 74 years, range: 65–86) were enrolled and administered either VEN at a dose of 400 mg (n = 60), 800 mg (n = 74) or 1200 mg (n = 11) co-administered daily with 20 mg/m2 of DEC on days 1–5 or 75 mg/m2 of AZA on days 1–7, each 28-day cycle.2

Key findings:

  • Safety

    • Most common grade 3–4 adverse events (AEs) occurring in ≥ 25% of patients include febrile neutropenia (43%), thrombocytopenia (24%), decreased WBC count (31%) and anemia 25%) 
    • 30-day mortality rate: 3% (5/145)
  • Efficacy

    • CR/CRi rate in all patients: 67% (97/145)
      • Median duration of CR/CRi: 11.3 months
    • CR/CRi rate in patients receiving VEN (400 mg) plus AZA: 76%
      • Median duration of response CR/CRi: NR (5.6–NR)
    • CR/CRi rate in patients receiving VEN (800 mg) plus AZA: 71%
    • Median OS: 17.5 months (12.3–NR)
    • Median OS in patients receiving 400 mg VEN: NR (11.0–NR)
  • Minimal residual disease (MRD) assessment demonstrated that 29% (28/97) of patients with CR/CRi achieved MRD negative status (MRD negativity was defined as less than 10-3 leukemic cells at any measurement in bone marrow aspirates)

The speaker concluded by stating that the “preliminary data suggest that 400 mg of VEN has the optimal benefit-risk profile in combination with DEC or AZA, which demonstrated a tolerable safety profile with deep responses and durable outcomes in elderly patients with AML”.  Courtney DiNardo discusses this study in an interview with the AML Global Portal.

  1. DiNardo C. D. et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018 Feb; 19(2): 216–228. DOI: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.
  2. DiNardo C. D. et al. Durable response with venetoclax in combination with decitabine or azacitadine in elderly patients with acute myeloid leukemia (AML). J Clin Oncol. 36, 2018 (suppl; abstr 7010).

Your opinion matters

On average, how many patients with acute myeloid leukemia do you see in a month?
7 votes - 16 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox